Century Sage Scientific Holdings Ltd (1450) AI Stock Analysis

• Market Cap: HK$1.68B
• Dividend Yield: N/A
• Average Volume (3M): 1.96M
• Price to Earnings (P/E): 28.9
• Beta (1Y): 0.37
• Revenue Growth: -1.52%
• EPS Growth: -67.16%
• Country: HK
• Employees: 1,163
• Sector: Technology
• Sector Strength: 88
• Industry: Software - Application
• EPS (TTM): 0.05
• Shares Outstanding: 1,387,203,100
• 10 Day Avg. Volume: 2,198,140
• 30 Day Avg. Volume: 1,964,156
• PEG Ratio: -0.57
• Price to Book (P/B): 3.34
• Price to Sales (P/S): 1.12
• P/FCF Ratio: -30.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.48
• Revenue Forecast (FY): HK$14.52B

• Rating: 64 Neutral
• Price Target: HK$1.50 ▲(23.97% Upside)

The overall stock score of 64 reflects strong technical momentum and a solid financial position, despite challenges in cash flow and valuation concerns. The absence of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding demand for the company's video solutions, enhancing its market position and supporting long-term business sustainability.

Balance Sheet Health

A strong equity ratio suggests financial stability, providing the company with flexibility to invest in growth opportunities and weather economic fluctuations.

Gross Profit Margin

A high gross profit margin reflects effective cost control and pricing power, which can support profitability and competitive advantage in the long term.

Negative Factors

Net Profit Margin Decline

A declining net profit margin suggests rising costs or operational inefficiencies, which could hinder profitability and require strategic adjustments.

Cash Flow Challenges

Zero cash flow generation can limit the company's ability to invest in growth, pay down debt, or return capital to shareholders, impacting long-term financial health.

Profitability Challenges

A moderate EBIT margin indicates potential issues in operational efficiency or cost management, which could affect the company's ability to sustain profits over time.

Century Sage Scientific Holdings Ltd Business Overview & Revenue Model

Company Description

Century Sage Scientific Holdings Ltd (1450) is a biotechnology and life sciences company focused on the research, development, and commercialization of innovative medical technologies and solutions. The company operates primarily in the health and wellness sector, offering a range of products and services that aim to improve patient outcomes and enhance the quality of life. Its core offerings include diagnostic tools, medical devices, and related services that cater to both healthcare providers and consumers.

How the Company Makes Money

Century Sage Scientific Holdings Ltd generates revenue through multiple streams, primarily by selling its proprietary medical devices and diagnostic products to hospitals, clinics, and healthcare professionals. The company also engages in research collaborations and partnerships with pharmaceutical firms, which often involve joint development projects that can lead to revenue-sharing agreements or upfront licensing fees. Additionally, the company may derive income from providing consulting services related to its technologies and from grants or funding associated with its research initiatives. Overall, the combination of product sales, strategic partnerships, and service offerings constitutes the core of its revenue model.

Century Sage Scientific Holdings Ltd Financial Statement Overview

Summary

Century Sage Scientific Holdings Ltd exhibits robust revenue growth and a solid balance sheet, underscoring its potential for long-term stability. However, the decline in net profit margin and cash flow generation pose potential risks to financial health. Continued focus on operational efficiency and liquidity management will be crucial for future performance.

Income Statement

The income statement reflects a strong revenue growth trajectory, with total revenue increasing significantly from 2023 to 2024. Gross profit margin is solid at 47.9%, indicating efficient cost management. However, the net profit margin has decreased to 6.5% from 11.1% in the previous year, suggesting higher expenses or lower operational efficiency. The EBIT margin is moderate at 8.5%, showing some profitability challenges.

Balance Sheet

The balance sheet shows a healthy equity ratio of 45.3%, indicating a stable capital structure. The debt-to-equity ratio is moderate at 0.60, reflecting manageable leverage levels. Return on equity is strong at 19.5%, demonstrating efficient use of equity capital. Overall, the balance sheet presents a balanced financial position with no significant red flags.

Cash Flow

The cash flow statement reveals challenges with cash generation, as operating and free cash flows are zero for 2024. This could indicate issues with liquidity or reinvestment capacity. The lack of free cash flow growth and operating cash flow to net income ratio suggest potential cash management issues despite previous years showing positive cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.25B	1.25B	1.07B	425.61M	202.79M	153.31M
Gross Profit	549.39M	599.30M	566.91M	189.80M	60.33M	55.85M
EBITDA	90.77M	119.87M	184.30M	19.76M	-22.52M	-44.96M
Net Income	54.00M	81.71M	119.46M	-9.21M	-61.62M	-97.53M
Balance Sheet
Total Assets	1.01B	923.92M	754.59M	446.91M	422.68M	498.64M
Cash, Cash Equivalents and Short-Term Investments	235.59M	113.32M	149.54M	50.93M	111.06M	12.78M
Total Debt	51.70M	252.83M	168.96M	151.23M	182.62M	182.12M
Total Liabilities	522.86M	510.21M	452.88M	343.92M	334.29M	392.86M
Stockholders Equity	493.30M	418.99M	297.51M	93.30M	65.80M	80.88M
Cash Flow
Free Cash Flow	80.73M	-45.69M	167.14M	-6.90M	7.43M	-2.52M
Operating Cash Flow	90.66M	-27.58M	182.99M	-2.08M	7.81M	-1.61M
Investing Cash Flow	-23.23M	-58.44M	-74.47M	32.34M	4.28M	-3.18M
Financing Cash Flow	-35.38M	52.47M	-10.28M	-34.83M	36.10M	5.00M

Century Sage Scientific Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1450, the sentiment is Positive. The current price of 1.21 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.11, and above the 200-day MA of 1.01, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.18 is Neutral, neither overbought nor oversold. The STOCH value of 89.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1450.

Century Sage Scientific Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1450	64 Neutral	HK$1.68B	28.95	11.90%	―	-1.52%	-67.16%
1588	64 Neutral	HK$2.60B	30.86	8.51%	―	12.46%	―
1808	62 Neutral	HK$732.22M	6.84	27.53%	―	421.56%	328.43%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
1675	61 Neutral	HK$6.97B	15.97	6.90%	3.40%	-17.90%	56.67%
1782	48 Neutral	HK$3.24B	-40.99	-37.61%	―	-16.86%	-7.51%
8083	43 Neutral	HK$4.43B	-48.21	-8.12%	―	3.97%	-211.11%

Century Sage Scientific Holdings Ltd Corporate Events

Be Friends Holding Limited Passes Key Resolution at EGM

Be Friends Holding Limited, a company incorporated in the Cayman Islands, announced the successful passage of an ordinary resolution at its Extraordinary General Meeting held on 7 November 2025. The resolution, which involved the ratification and approval of an Equity Purchase Agreement and its supplemental agreement, was passed with 100% of the votes cast in favor. This development marks a significant step for the company, potentially impacting its strategic operations and aligning with shareholder interests, as a substantial portion of shareholders abstained from voting due to existing interests.

Be Friends Holding Limited Announces EGM for Equity Purchase Approval

Be Friends Holding Limited has announced an Extraordinary General Meeting (EGM) to be held on November 7, 2025, in Hangzhou City, China. The meeting will address the ratification and approval of an Equity Purchase Agreement and its associated transactions, which have been detailed in a company circular. This move is significant for the company’s strategic operations and may impact its market positioning and shareholder interests.

Be Friends Holding Limited Reports Mixed GMV Results for 2025

Be Friends Holding Limited announced a Gross Merchandise Volume (GMV) of approximately RMB2.55 billion for the third quarter of 2025, marking a 12.07% decrease compared to the same period in 2024. However, the cumulative GMV for the first three quarters of 2025 increased by 7.56% compared to the previous year, indicating growth in the company’s operations despite the quarterly decline.

Century Sage Scientific Holdings Ltd Grants 865,000 Shares Under Award Plan

Century Sage Scientific Holdings Ltd announced the grant of 865,000 awarded shares to selected participants under its Share Award Plan, aimed at recognizing and incentivizing key contributors within the company. This move, which includes shares allocated to senior managers and employees, aligns with the company’s strategic objectives and is contingent upon achieving performance targets, potentially impacting the company’s operational efficiency and stakeholder interests.

Century Sage Scientific Holdings Ltd Amends Acquisition Agreement

Century Sage Scientific Holdings Ltd has announced a supplemental agreement related to a significant acquisition. The company is amending the terms and structure of its acquisition of equity interests in a target company, resulting in the partnership becoming an indirect wholly-owned entity and the target company becoming an indirect wholly-owned subsidiary. This strategic move is expected to enhance the company’s operational capabilities and market positioning.

Be Friends Holding Limited Delays Circular Dispatch for Acquisition

Be Friends Holding Limited has announced a delay in the dispatch of a circular related to its acquisition of the entire equity interests in a target company. The circular, which includes details on the acquisition terms and recommendations from the Independent Board Committee, was initially expected to be sent to shareholders by September 12, 2025. However, the dispatch has been postponed to on or before September 30, 2025, due to the need for additional time to finalize certain information.